Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Chemsyn Pharm CoBJSE:920656 39 Return-on-Tangible-Equity is 11.61% as of Mar. 2026, which is 64% below its 10-year median of 32.37. GuruFocus rates BJSE:920656 with a GF Score™ of 39/100. The stock has 4 warning signs investors should review. Among 18 Healthcare Plans companies, Zhejiang Chemsyn Pharm Co ranks worse than 61.11% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Zhejiang Chemsyn Pharm Co's annualized net income for the quarter that ended in Mar. 2026 was ¥80.4 Mil. Zhejiang Chemsyn Pharm Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥692.0 Mil. Therefore, Zhejiang Chemsyn Pharm Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.61%.
The historical rank and industry rank for Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity or its related term are showing as below:
BJSE:920656'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.69 Med: 32.37 Max: 70.61
Current: 11.45
During the past 12 years, Zhejiang Chemsyn Pharm Co's highest Return-on-Tangible-Equity was 70.61%. The lowest was 8.69%. And the median was 32.37%.
BJSE:920656's Return-on-Tangible-Equity is ranked worse than 61.11% of 18
companies
in the Healthcare Plans industry
Industry Median: 14.915
vs BJSE:920656: 11.45
Zhejiang Chemsyn Pharm Co (BJSE:920656) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Zhejiang Chemsyn Pharm Co Return-on-Tangible-Equity Related Terms
Zhejiang Chemsyn Pharm Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Chemsyn Pharm Co Return-on-Tangible-Equity Chart
BJSE:920656 vs UNH, CVS, ELV: Return-on-Tangible-Equity Comparison
For the Healthcare Plans subindustry, Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Chemsyn Pharm Co Return-on-Tangible-Equity vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.61% mean?
Zhejiang Chemsyn Pharm Co (BJSE:920656) has a Return-on-Tangible-Equity of 11.61% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang Chemsyn Pharm Co and its competitors. This is 64% below median its historical median of 32.37. Over the past decade, Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity has ranged from 8.69 to 70.61. According to the industry distribution chart, Zhejiang Chemsyn Pharm Co ranks #11 out of 18 companies in the Healthcare Plans industry, placing it in the top 61.1%.
Is Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity too high?
Zhejiang Chemsyn Pharm Co's current Return-on-Tangible-Equity of 11.61% is 64% below median its 10-year median of 32.37. Over the past 10 years, this metric has ranged from a low of 8.69 to a high of 70.61. The Healthcare Plans industry median Return-on-Tangible-Equity is 14.92. Zhejiang Chemsyn Pharm Co's value of 11.61% is 22.2% below this industry median. Based on the distribution chart, Zhejiang Chemsyn Pharm Co ranks #11 out of 18 companies in the Healthcare Plans industry, which is below the industry midpoint. Overall, Zhejiang Chemsyn Pharm Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Chemsyn Pharm Co's Return-on-Tangible-Equity compare to UNH and CVS?
According to the Healthcare Plans industry distribution chart, Zhejiang Chemsyn Pharm Co ranks #11 out of 18 companies for Return-on-Tangible-Equity. This places Zhejiang Chemsyn Pharm Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 14.92. Zhejiang Chemsyn Pharm Co's value of 11.61% is 22.2% below this benchmark. Historically, Zhejiang Chemsyn Pharm Co's own Return-on-Tangible-Equity has ranged from 8.69 to 70.61 over the past decade. While the company's 10-year median is 32.37 vs. the industry median of 14.92, Zhejiang Chemsyn Pharm Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Plans company?
The median Return-on-Tangible-Equity among Healthcare Plans companies is 14.92, based on 18 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Chemsyn Pharm Co's current Return-on-Tangible-Equity of 11.61% is 22.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang Chemsyn Pharm Co and its competitors. For the Healthcare Plans industry, the median Return-on-Tangible-Equity is 14.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Chemsyn Pharm Co's current Return-on-Tangible-Equity is 11.61%, which is 64% below median its own 10-year median of 32.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Chemsyn Pharm Co stock overvalued right now?
Zhejiang Chemsyn Pharm Co (BJSE:920656) has a current Return-on-Tangible-Equity of 11.61%. The current Return-on-Tangible-Equity is 11.61%, which is 64% below median its 10-year median of 32.37 and 22.2% below the Healthcare Plans industry median of 14.92. Zhejiang Chemsyn Pharm Co's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Zhejiang Chemsyn Pharm Co (BJSE:920656), the current Return-on-Tangible-Equity is 11.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhejiang Chemsyn Pharm Co Ltd is engaged in Research, development, production and sales of veterinary drug raw materials, pharmaceutical raw materials and intermediates.
39GF Score
Get the complete analysis for BJSE:920656
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920656 has been successfully added to your 
